Dosimetry of 223Ra-chloride: dose to normal organs and tissues

  • Michael Lassmann
  • Dietmar Nosske
Original Article



223Ra-Chloride (also called Alpharadin®) targets bone metastases with short range alpha particles. In recent years several clinical trials have been carried out showing, in particular, the safety and efficacy of palliation of painful bone metastases in patients with castration-resistant prostate cancer using 223Ra-chloride. The purpose of this work was to provide a comprehensive dosimetric calculation of organ doses after intravenous administration of 223Ra-chloride according to the present International Commission on Radiological Protection (ICRP) model for radium.


Absorbed doses were calculated for 25 organs or tissues.


Bone endosteum and red bone marrow show the highest dose coefficients followed by liver, colon and intestines. After a treatment schedule of six intravenous injections with 0.05 MBq/kg of 223Ra-chloride each, corresponding to 21 MBq for a 70 kg patient, the absorbed alpha dose to the bone endosteal cells is about 16 Gy and the corresponding absorbed dose to the red bone marrow is approximately 1.5 Gy.


The comprehensive list of dose coefficients presented in this work will assist in comparing and evaluating organ doses from various therapy modalities used in nuclear medicine and will provide a base for further development of patient-specific dosimetry.


223Ra-Chloride Alpharadin® Bone metastases Castration-resistant prostate cancer Dosimetry 


Conflicts of interest



  1. 1.
    Bruland ØS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 2006;12:6250s–7s.PubMedCrossRefGoogle Scholar
  2. 2.
    Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587–94.PubMedCrossRefGoogle Scholar
  3. 3.
    Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11:4451–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Nilsson S, Strang P, Aksnes AK, Franzèn L, Olivier P, Pecking A, et al. A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012;48:678–86.PubMedCrossRefGoogle Scholar
  5. 5.
    Lewington V, Lamey R, Staudacher K, Vogelzang N. Radium-223 chloride: radiation safety, tolerability, and survival gain in patients with castration-resistant prostate cancer (CRPC) and bone metastases. J Nucl Med 2012;53(Suppl 1):222.Google Scholar
  6. 6.
    ICRP. Publication 67: Age-dependent doses to members of the public from intake of radionuclides: part 2 ingestion dose coefficients. Ann ICRP 1992;22.Google Scholar
  7. 7.
    Lassmann M, Nosske D, Reiners C. Therapy of ankylosing spondylitis with 224Ra-radium chloride: dosimetry and risk considerations. Radiat Environ Biophys 2002;41:173–8.PubMedGoogle Scholar
  8. 8.
    Salmon PL, Onischuk YN, Bondarenko OA, Lanyon LE. Alpha-particle doses to cells of the bone remodeling cycle from alpha-particle-emitting bone-seekers: indications of an antiresorptive effect of actinides. Radiat Res 1999;152:S43–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Leggett RW. A generic age-specific biokinetic model for calcium-like elements. Radiat Prot Dosimetry 1992;41:183–98.Google Scholar
  10. 10.
    ICRP. Publication 71: Age-dependent doses to members of the public from intake of radionuclides: part 4 inhalation dose coefficients. Ann ICRP 1995;25.Google Scholar
  11. 11.
    ICRP. Publication 110: Adult reference computational phantoms. Ann ICRP 2009;2.Google Scholar
  12. 12.
    ICRP. Publication 30 (part 1): Limits for intakes of radionuclides by workers. Ann ICRP 1979;2.Google Scholar
  13. 13.
    ICRP. Publication 100. Human alimentary tract model for radiological protection. Ann ICRP 2006;36:1–2.Google Scholar
  14. 14.
    Howell RW, Goddu SM, Narra VR, Fisher DR, Schenter RE, Rao DV. Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: relative biological effectiveness of alpha-particle emitters in vivo. Radiat Res 1997;147:342–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 2010;51:311–28.PubMedCrossRefGoogle Scholar
  16. 16.
    ICRP. Publication 103: The 2007 recommendations of the International Commission on Radiological Protection. Ann ICRP 2007;2007:37.Google Scholar
  17. 17.
    Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A, et al. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 2008;35:1934–40.PubMedCrossRefGoogle Scholar
  18. 18.
    Hobbs RF, Song H, Watchman CJ, Bolch WE, Aksnes AK, Ramdahl T, et al. A bone marrow toxicity model for 223Ra alpha-emitter radiopharmaceutical therapy. Phys Med Biol 2012;57:3207–22.PubMedCrossRefGoogle Scholar
  19. 19.
    Hindorf C, Chittenden S, Aksnes AK, Parker C, Flux GD. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl Med Commun 2012;33:726–32.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of Nuclear MedicineUniversity of WürzburgWürzburgGermany
  2. 2.Department of Radiation and HealthFederal Office for Radiation Protection (BfS)OberschleißheimGermany

Personalised recommendations